Bispecific antibodies: potential immunotherapies for HIV treatment

Publication date: Available online 22 October 2018Source: MethodsAuthor(s): Giulia Fabozzi, Amarendra Pegu, Richard A. Koup, Constantinos PetrovasAbstractBispecific (bs) antibodies (Abs, bsAbs) are engineered immunoglobulins that contain two different antigen-binding sites in one molecule. bsAbs can be divided in two molecular formats; the IgG-like and non-IgG like. The structural elements of each format have implications for engaging the immune system. Elimination of HIV will need sophisticated approaches with immunotherapies being one of the strategies under investigation. Furthermore, HIV genetic variability and functional compromise of the adaptive CTL response complicate the potential usefulness of some immunotherapeutic strategies. Inclusion of novel HIV neutralizing Abs with high potency and breadth as components of bsAbs could represent alternative strategies for virus elimination by harnessing the adaptive immune response in vivo.
Source: Methods - Category: Molecular Biology Source Type: research